The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

Researchers discovered combining the brain-penetrating antipsychotic drug pimozide with a clinically investigative glutamine metabolism inhibitor, CB-839, can overcome tumor resistance and effectively ...

Glioblastoma is the most aggressive and deadliest form of brain cancer. Most patients survive only about a year after diagnosis, and just 5% make it to five years. Dr. Minesh P. Mehta is leading the ...

INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA ...

Educational and financial disparities significantly affect glioblastoma care satisfaction and access to information on testing and trials. Participants without a college degree were less informed ...

Glioblastoma (GBM) is a rare and deadly disease: roughly 12,000 new patients are diagnosed every year in the US, a country of 330 million people. Most GBM patients die within 15 months and fewer than ...

Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's ...

Study lead author Deliang Guo, PhD, the founding director of the Center for Cancer Metabolism at The Ohio State University Comprehensive Cancer Center -- James Cancer Hospital and Solove Research ...